Cardiovascular Research Advance Access first published online on December 4, 2007
This version [Corrected Proof] published online on January 16, 2008
Cardiovascular Research, doi:10.1093/cvr/cvm087
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport
1 Baker Heart Research Institute, PO Box 6492, St. Kilda Road Central, Melbourne, Victoria 8008, Australia
2 Hoffmann La Roche Ltd, Basel, Switzerland
* Corresponding author. Tel: +61 3 85321363; fax: +61 3 85321100. E-mail address: dmitri.sviridov{at}baker.edu.au
Aims: Cholesteryl ester transfer protein (CETP) has a well-established role in lipoprotein metabolism, but the effect of its overexpression or inhibition on the efficiency of reverse cholesterol transport (RCT) is unclear.
Methods and results: Neither overexpression of CETP nor treatment with CETP inhibitor Torcetrapib of RAW 264.7 macrophages or HepG2 hepatocytes affected cholesterol efflux in vitro. Overexpression of CETP or treatment with Torcetrapib, respectively, stimulated or inhibited HDL cholesteryl ester uptake by HepG2 but not by RAW 264.7 cells. When RAW 264.7 cells transfected with CETP or ATP binding cassette transporter A1 (ABCA1) were injected intraperitoneally into mice, cholesterol egress from macrophages was elevated for ABCA1- but not for CETP-transfected macrophages. Systemic expression of CETP in mice by adenoviral infection stimulated egress of cholesterol to plasma and liver without affecting HDL levels. Treatment with Torcetrapib did not affect appearance of macrophage cholesterol in plasma and liver, but inhibited its excretion into feces. Treatment of hamsters with Torcetrapib led to elevation of HDL cholesterol, an increase in the capacity of plasma to support cholesterol efflux, and increased egress of cholesterol from macrophages to plasma and feces in vivo.
Conclusion: Both increased (mice study) and decreased (hamster study) CETP activity could result in enhanced RCT.
KEYWORDS Cholesteryl ester transfer protein; Reverse cholesterol transport; CETP inhibition; Lipoproteins; Cholesterol; Atherosclerosis
Time for primary review: 25 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Mukhamedova, G. Escher, W. D'Souza, U. Tchoua, A. Grant, Z. Krozowski, M. Bukrinsky, and D. Sviridov Enhancing apolipoprotein A-I-dependent cholesterol efflux elevates cholesterol export from macrophages in vivo J. Lipid Res., November 1, 2008; 49(11): 2312 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Levy High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench Cardiovasc Res, March 1, 2008; 77(4): 614 - 615. [Full Text] [PDF]
|
|